Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 39, Issue 216, 2005, Pages 20-33

  Amin, Mahul ^a,l   Boccon Gibod, Liliane ^b   Egevad, Lars ^c   Epstein, Jonathan I ^d   Humphrey, Peter A ^e   Mikuz, Gregor ^f   Newling, Don ^g   Nilsson, Sten ^c   Sakr, Wael ^h   Srigley, John R ⁱ   Wheeler, Thomas M ^j   Montironi, Rodolfo ^k  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^g ASTRAZENECA   (United Kingdom)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^l EMORY UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

Gleason score; Guidelines; Needle biopsy; Perineural invasion; Predictive factor; Prognostic factor; Prostate cancer; Recommendations; Reporting; Standards; Tumor volume

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

ASSOCIATION OF DIRECTORS OF ANATOMIC AND SURGICAL PATHOLOGISTS; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; COLLEGE OF AMERICAN PATHOLOGISTS; CONFERENCE PAPER; EUROPEAN SOCIETY OF UROLOGIC PATHOLOGY; EUROPEAN STUDY OF SCREENING FOR PROSTATE CANCER; GLEASON SCORE; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; INTERNATIONAL COOPERATION; MALE; MEDICAL DOCUMENTATION; NEEDLE BIOPSY; PATHOLOGY; PERINEURAL INVASION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; ROYAL SOCIETY OF PATHOLOGISTS; SURGICAL PATHOLOGY REPORT; TUMOR LOCALIZATION; TUMOR VOLUME; ARTICLE; ASSOCIATION OF DIRECTORS OF ANATOMIC AND SURGICAL PATHOLOGIST; COLLEGE OF AMERICAN PATHOLOGIST; DIAGNOSTIC VALUE; DISEASE MARKER; EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER; MEDICAL SOCIETY; MOLECULAR BIOLOGY; PATIENT CARE; WORLD HEALTH ORGANIZATION; CARCINOMA; FORECASTING; GENETICS; PROSTATE TUMOR; REVIEW; UROLOGY;

BIOPSY, NEEDLE; CARCINOMA; FORECASTING; HUMANS; MALE; NEOPLASM INVASIVENESS; PATHOLOGY; PRACTICE GUIDELINES; PROGNOSIS; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UROLOGY; WORLD HEALTH ORGANIZATION;

EID: 22144443212     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: 10.1080/03008880510030923     Document Type: Conference Paper

References (114)

1. Miyake H, Sakai I, Harada K, Hara I, Eto H. Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy. Int J Urol 2004;11:402-6.
2. Presti JC Jr. Prostate biopsy: how many cores are enough? Urol Oncol 2003;21:135-40.
3. Peyromaure M, Ravery V, Boccon-Gibod L. Biopsies of the transitional zone: impact on the detection of prostatic cancer and prognostic value. Prog Urol 2002;12:8-14.
4. Ravery V, Billebaud T, Toublanc M, Boccon-Gibod L, Hermieu JF, Moulinier F, et al. Diagnostic value of ten systematic TRUS-guided prostate biopsies. Eur Urol 1999;35:298-303.
5. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-91; discussion 91-2.
6. Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond ME. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000;124:1034-9.
7. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
8. Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Ayala AG. Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 1996;105:667-70.
9. The Royal College of Pathologists. Standards and minimum datasets for reporting cancer. Minimum dataset for prostate cancer histopathology reports. London: The Royal College of Pathologists; 2000.
10. Boccon-Gibod L, van der Kwast TH, Montironi R, Boccon-Gibod L, Bono A, European Society of Uropathology, et al. Handling and pathology reporting of prostate biopsies. Eur Urol 2004;46:177-81.
11. Van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003;56:336-40.
12. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996;156:1375-80.
13. Zhou M, Epstein JI. The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers. Pathology 2003;35:472-9.
14. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol 2004;171:1093-7.
15. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, et al. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2003;98:2344-50.
16. Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K, et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003;170:1203-8.
17. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 1997;10:612-29.
18. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol 2004;17:316-27.
19. Shannon RL, Ro JY, Grignon DJ, Ordonez NG, Johnson DE, Mackay B, et al. Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients. Cancer 1992;69:2676-82.
20. Ro JY, Grignon DJ, Ayala AG, Fernandez PL, Ordonez NG, Wishnow KI. Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol 1990;21:593-600.
21. Ro JY, el-Naggar A, Ayala AG, Mody DR, Ordonez NG. Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol 1988;12:453-60.
22. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999;23:1471-9.
23. Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol 2004;28:651-7.
24. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147:804-7.
25. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80.
26. Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11-7.
27. Amin MB, Grignon D, Humphrey PH, Srigley JR. Gleason grading of prostate cancer: a contemporary approach. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
28. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
29. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-7.
30. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997;79:337-44.
31. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997;49:23-30.
32. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003;61:589-95.
33. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, Shariat S, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844-9.
34. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
35. Yang XJ, Lecksell K, Potter SR, Epstein JI. Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology 1999;54:528-32.
36. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003;170:459-63.
37. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol 2000;164:81-8.
38. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001;166:1702-6.
39. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
40. Kunz GM Jr, Epstein JI. Should each core with prostate cancer be assigned a separate Gleason score? Hum Pathol 2003;34:911-4.
41. Rubin MA, Bismar TA, Curtis S, Montie JE. Prostate needle biopsy reporting: how are the surgical members of the society of urologic oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol 2004;28:946-52.
42. Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 2004;171:200-3.
43. Augustin H, Eggert T, Wenske S, Karakiewicz PI, Palisaar J, Daghofer F, et al. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 2004;171:177-81.
44. Grober ED, Tsihlias J, Jewett MA, Sweet JM, Evans AJ, Trachtenberg J, et al. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol 2004;11:2157-62.
45. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, et al. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000;56:730-4.
46. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
47. Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 2002;167:2440-2.
48. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 2000;24:477-8.
49. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001;32:74-80.
50. Fleshner NE, Cookson MS, Soloway SM, Fair WR. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology 1998;52:659-62.
51. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281-6.
52. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002;167:516-20.
53. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998;52:1079-84.
54. Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002;168:1994-9.
55. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 2003;169:2136-41.
56. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-72.
57. Ravery V, Szabo J, Toublanc M, Boccon-Gibod LA, Billebaud T, Hermieu JF, et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996;77:724-8.
58. Hammerer P, Henke RP, Hubner D, Huland H. Preoperative assessment of tumor aggressiveness in localized prostatic carcinoma. Urologe A 1995;34:413-8.
59. Rubin MA, Mucci NR, Manley S, Sanda M, Cushenberry E, Strawderman M, et al. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively? J Urol 2001;165:114-8.
60. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998;11:543-51.
61. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
62. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score
63. Lewis JS Jr, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 2002;118:442-50.
64. Bismar TA, Lewis JS Jr, Vollmer RT, Humphrey PA. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003;27:432-40.
65. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004;17:307-15.
66. Freedland SJ, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Dorey F, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003;61:742-7.
67. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Urology 2002;60:84-8.
68. Cohen RJ, Stables S. Intraprostatic fat. Hum Pathol 1998;29:424-5.
69. Amin MB, Bostwick DG. Pigment in prostatic epithelium and adenocarcinoma: a potential source of diagnostic confusion with seminal vesicular epithelium. Mod Pathol 1996;9:791-5.
70. Vallancien G, Prapotnich D, Veillon B, Brisset JM, Andre-Bougaran J. Seminal vesicle biopsies in the preoperative staging of prostatic cancer. Eur Urol 1991;19:196-200.
71. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Bill-ebaud T, Delmas V, Meulemans A, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-6.
72. Viglione MP, Potter S, Partin AW, Lesniak MS, Epstein JI. Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy? Hum Pathol 2002;33:796-800.
73. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566-76.
74. Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 2004;58:19-24.
75. Javidan J, Wood DP. Clinical interpretation of the prostate biopsy. Urol Oncol 2003;21:141-4.
76. Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 2003;97:1884-93.
77. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001,91:2196-204.
78. De la Taille A, Katz A, Bagiella E, Olsson CA, O'Toole KM, Rubin MA. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999;54:1039-43.
79. Holmes GF, Walsh PC, Pound CR, Epstein JI. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. Urology 1999;53:752-6.
80. Vargas SO, Jiroutek M, Welch WR, Nucci MR, D'Amico AV, Renshaw AA. Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection. Am J Clin Pathol 1999;111:223-8.
81. Egan AJ, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997;21:1496-500.
82. Bonin SR, Hanlon AL, Lee WR, Movsas B, al-Saleem TI, Hanks GE. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 1997;79:75-80.
83. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993;17:336-41.
84. Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 1998;159:1251-9.
85. Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998;41:1087-92.
86. Maru N, Ohori M, Kattan MW, Scardino PT, Wheeler TM. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol 2001;32:828-33.
87. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 2004;171:1122-7.
88. Ito K, Nakashima J, Mukai M, Asakura H, Ohigashi T, Saito S, et al. Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol Int 2003;70:297-302.
89. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-400.
90. Salomao DR, Graham SD, Bostwick DG. Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 1995;119:1050-4.
91. Bishara T, Ramnani DM, Epstein JI. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am J Surg Pathol 2004;28:629-33.
92. Naya Y, Ayala AG, Tamboli P, Babaian RJ. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urology 2004;63:503-8.
93. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079-85.
94. Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995;154:1295-9.
95. Mendrinos SE, Amin MB, Lim SD, Herrera CM, Srigley JR. Predictive value of pathologic parameters of high-grade prostatic intraepithelial neoplasia (HGPIN) in the initial biopsy for the subsequent detection of prostatic carcinoma (PCa). Mod Pathol 2004;17(Suppl 1):168A.
96. Gokden NRK, Humphrey PA. High grade prostatic intraepithelial neoplasia in needle biopsy tissue as a risk factor for detection of adenocarcinoma: current level of risk in a screening population. Mod Pathol 2004;16:152.
97. Ouyang RC, Kenwright DN, Nacey JN, Delahunt B. The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy. BJU Int 2001;87:70-4.
98. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, et al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. Urology 1998;51:749-57.
99. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 1997;21:1489-95.
100. Gokden N, Roehl KA, Catalona WJ, Humphrey PA. High-grade prostatic intraepithelial neoplasia in needle biopsy as a risk factor for detection of adenocarcinoma: current level of risk in a screening population. Urology 2005; In press.
101. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy. J Urol 2003;170:1184-8.
102. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002;26:1161-8.
103. Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26:1588-96.
104. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol 2002;118:202-7.
105. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004;22:2133-40.
106. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
107. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-8.
108. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
109. Ross JS, Jennings TA, Nazeer T, Sheehan CE, Fisher HA, Kauffman RA, et al. Prognostic factors in prostate cancer. Am J Clin Pathol 2003;120(Suppl):S85- 100.
110. Visakorpi T. The molecular genetics of prostate cancer. Urology 2003;62:3-10.
111. Isaacs W, Kainu T. Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 2001;23:36-41.
112. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004;171:1419-23.
113. Zhou W, Goodman M, Lyles RH, Lim SD, Williams TY, Rusthoven KE, et al. Surgical margin and Gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance. Prostate 2004;61:81-91.
114. Rogatsch H, Hittmair A, Reissigl A, Mikuz G, Feichtinger H. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997;182:205-10.